{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T02:38:36Z","timestamp":1787020716686,"version":"build-2736575974"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Radiat Oncol"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1186\/s13014-017-0894-9","type":"journal-article","created":{"date-parts":[[2017,9,21]],"date-time":"2017-09-21T05:45:22Z","timestamp":1505972722000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Comparison of volumetric-modulated arc therapy using simultaneous integrated boosts (SIB-VMAT) of 45\u00a0Gy\/55\u00a0Gy in 25 fractions with conventional radiotherapy in preoperative chemoradiation for rectal cancers: a propensity score case-matched analysis"],"prefix":"10.1186","volume":"12","author":[{"given":"Hideomi","family":"Yamashita","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soichiro","family":"Ishihara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroaki","family":"Nozawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazushige","family":"Kawai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomomichi","family":"Kiyomatsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kae","family":"Okuma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Osamu","family":"Abe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshiaki","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keiichi","family":"Nakagawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,9,21]]},"reference":[{"key":"894_CR1","doi-asserted-by":"crossref","first-page":"2479","DOI":"10.1093\/annonc\/mds236","volume":"23","author":"HJ Schmoll","year":"2012","unstructured":"Schmoll HJ, Van Cutsem E, Stein A, Valentini V, Glimelius B, Haustermans K, et al. ESMO consensus guidelines for management of patients with colon and rectal cancer. a personalized approach to clinical decision making. Ann Oncol. 2012;23:2479\u2013516.","journal-title":"Ann Oncol"},{"key":"894_CR2","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1056\/NEJMoa040694","volume":"351","author":"R Sauer","year":"2004","unstructured":"Sauer R, Becker H, Hohenberger W, R\u00f6del C, Wittekind C, Fietkau R, et al. German rectal cancer study group. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med. 2004;351:1731\u201340.","journal-title":"N Engl J Med"},{"key":"894_CR3","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1056\/NEJMoa060829","volume":"355","author":"JF Bosset","year":"2006","unstructured":"Bosset JF, Collette L, Calais G, Mineur L, Maingon P, Radosevic-Jelic L, , et al.; EORTC radiotherapy group trial 22921. Chemotherapy with preoperative radiotherapy in rectal cancer. N Engl J Med 2006; 355: 1114\u20131123.","journal-title":"N Engl J Med"},{"key":"894_CR4","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.radonc.2014.10.006","volume":"113","author":"A Sainato","year":"2014","unstructured":"Sainato A, Cernusco Luna Nunzia V, Valentini V, De Paoli A, Maurizi ER, Lupattelli M, et al. No benefit of adjuvant fluorouracil Leucovorin chemotherapy after neoadjuvant chemoradiotherapy in locally advanced cancer of the rectum (LARC): long term results of a randomized trial (I-CNR-RT). Radiother Oncol. 2014;113:223\u20139.","journal-title":"Radiother Oncol"},{"key":"894_CR5","unstructured":"National Comprehensive Cancer Network Guidelines, Rectal Cancer, Version 3. 2017. \nhttps:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/rectal.pdf\n\n."},{"issue":"28","key":"894_CR6","doi-asserted-by":"crossref","first-page":"4620","DOI":"10.1200\/JCO.2006.06.7629","volume":"24","author":"JP G\u00e9rard","year":"2006","unstructured":"G\u00e9rard JP, Conroy T, Bonnetain F, Bouch\u00e9 O, Chapet O, Closon-Dejardin MT, et al. Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203. J Clin Oncol. 2006;24(28):4620\u20135.","journal-title":"J Clin Oncol"},{"key":"894_CR7","doi-asserted-by":"publisher","unstructured":"Picardi V, Macchia G, Guido A, Giaccherini L, Deodato F, Farioli A, et al. Preoperative chemoradiation with VMAT-SIB in rectal cancer: a phase II study. Clin Colorectal Cancer. 2017;16(1):16-22. doi:\n10.1016\/j.clcc.2016.06.004\n\n. Epub 2016 Jun 23. PMID:27435759","DOI":"10.1016\/j.clcc.2016.06.004"},{"key":"894_CR8","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s13014-014-0311-6","volume":"10","author":"H Yamashita","year":"2015","unstructured":"Yamashita H, Takenaka R, Sakumi A, Haga A, Otomo K, Nakagawa K. Analysis of motion of the rectum during preoperative intensity modulated radiation therapy for rectal cancer using cone-beam computed tomography. Radiat Oncol. 2015;10:2.","journal-title":"Radiat Oncol"},{"issue":"5","key":"894_CR9","first-page":"505","volume":"26","author":"JG Guillem","year":"1999","unstructured":"Guillem JG, Cohen AM. Current issues in colorectal cancer surgery. Semin Oncol. 1999;26(5):505\u201313.","journal-title":"Semin Oncol"},{"issue":"21","key":"894_CR10","doi-asserted-by":"crossref","first-page":"3281","DOI":"10.3748\/wjg.14.3281","volume":"14","author":"RO Lindsetmo","year":"2008","unstructured":"Lindsetmo RO, Joh YG, Delaney CP. Surgical treatment for rectal cancer: an international perspective on what the medical gastroenterologist needs to know. World J Gastroenterol. 2008;14(21):3281\u20139.","journal-title":"World J Gastroenterol"},{"key":"894_CR11","doi-asserted-by":"publisher","unstructured":"Watanabe T, Itabashi M, Shimada Y, Tanaka S, Ito Y, Ajioka Y, et al. Japanese Society for Cancer of the Colon and Rectum (JSCCR) Guidelines 2014 for treatment of colorectal cancer. Int J Clin Oncol. 2015;20(2):207\u201339. Published online 2015 Mar 18. doi:\n10.1007\/s10147-015-0801-z\n\n.","DOI":"10.1007\/s10147-015-0801-z"},{"key":"894_CR12","doi-asserted-by":"publisher","unstructured":"Fokas E, Liersch T, Fietkau R, Hohenberger W, Beissbarth T, Hess C, et al. Tumor regression grading after preoperative chemoradiotherapy for locally advanced rectal carcinoma revisited: updated results of the CAO\/ARO\/AIO-94 trial. J Clin Oncol 2014; 32: 1554-1562. doi: \n10.1200\/JCO.2013.54.3769\n\n. \nhttp:\/\/www.R-project.org\/\n\n. PMID: 24752056.","DOI":"10.1200\/JCO.2013.54.3769"},{"key":"894_CR13","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1016\/j.ijrobp.2015.10.061","volume":"94","author":"E Cotte","year":"2016","unstructured":"Cotte E, Passot G, Decullier E, Maurice C, Glehen O, Fran\u00e7ois Y, et al. Pathologic response, when increased by longer interval, is a marker but not the cause of good prognosis in rectal cancer: 17-year follow-up of the Lyon R90-01 randomized trial. Int J Radiat Oncol Biol Phys. 2016;94:544\u201353.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"894_CR14","doi-asserted-by":"crossref","first-page":"2396","DOI":"10.1200\/JCO.1999.17.8.2396","volume":"17","author":"Y Francois","year":"1999","unstructured":"Francois Y, Nemoz CJ, Baulieux J, Vignal J, Grandjean JP, Partensky C, et al. Influence of the interval between preoperative radiation therapy and surgery on downstaging and on the rate of sphincter-sparing surgery for rectal cancer: the Lyon R90-01 randomized trial. J Clin Oncol. 1999;17:2396.","journal-title":"J Clin Oncol"},{"key":"894_CR15","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1245\/s10434-015-4927-z","volume":"23","author":"CR Huntington","year":"2016","unstructured":"Huntington CR, Boselli D, Symanowski J, Hill JS, Crimaldi A, Salo JC. Optimal timing of surgical resection after radiation in locally advanced rectal adenocarcinoma: an analysis of the national cancer database. Ann Surg Oncol. 2016;23:877\u201387.","journal-title":"Ann Surg Oncol"},{"key":"894_CR16","doi-asserted-by":"crossref","first-page":"2661","DOI":"10.1245\/s10434-008-9892-3","volume":"15","author":"H Tulchinsky","year":"2008","unstructured":"Tulchinsky H, Shmueli E, Figer A, Klausner JM, Rabau M. An interval >7 weeks between neoadjuvant therapy and surgery improves pathologic complete response and disease-free survival in patients with locally advanced rectal cancer. Ann Surg Oncol. 2008;15:2661\u20137.","journal-title":"Ann Surg Oncol"},{"key":"894_CR17","doi-asserted-by":"publisher","first-page":"1770","DOI":"10.1200\/JCO.2011.39.7901","volume":"30","author":"IJ Park","year":"2012","unstructured":"Park IJ, You YN, Agarwal A, Skibber JM, Rodriguez-Bigas MA, Eng C, et al. Neoadjuvant treatment response as an early response indicator for patients with rectal cancer. J Clin Oncol. 2012;30:1770\u20136. doi: \n10.1200\/JCO.2011.39.7901\n\n. PMID: 22493423 PMCID: PMC3383178","journal-title":"J Clin Oncol"},{"key":"894_CR18","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1200\/JCO.2009.25.8376","volume":"28","author":"JP G\u00e9rard","year":"2010","unstructured":"G\u00e9rard JP, Azria D, Gourgou-Bourgade S, et al. Comparison of two neoadjuvant chemoradiotherapy regimens for locally advanced rectal cancer: results of the phase III trial ACCORD 12\/405-Prodige 2. J Clin Oncol. 2010;28:1638\u201344.","journal-title":"J Clin Oncol"},{"key":"894_CR19","doi-asserted-by":"publisher","unstructured":"Russell MM, Ganz PA, Lopa S, Yothers G, Ko CY, Arora A, Atkins JN, Bahary N, Soori GS, Robertson JM, Eakle J, Marchello BT, Wozniak TF, Beart RW Jr, Wolmark N. Comparative effectiveness of sphincter-sparing surgery versus abdominoperineal resection in rectal cancer: patient-reported outcomes in National Surgical Adjuvant Breast and Bowel Project randomized trial R-04. Ann Surg. 2015;261(1):144-8. PMID:24670844 PMCID:PMC4379325 doi:\n10.1097\/SLA.0000000000000594\n\n.","DOI":"10.1097\/SLA.0000000000000594"},{"key":"894_CR20","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1016\/S1470-2045(15)00159-X","volume":"16","author":"C R\u00f6del","year":"2015","unstructured":"R\u00f6del C, Graeven U, Fietkau R, Hohenberger W, Hothorn T, Arnold D, et al. Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO\/ARO\/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2015;16:979\u201389.","journal-title":"Lancet Oncol"},{"key":"894_CR21","first-page":"588","volume":"27","author":"D Jiao","year":"2015","unstructured":"Jiao D, Zhang R, Gong Z, Liu F, Chen Y, Yu Q, et al. Fluorouracil-based preoperative chemoradiotherapy with or without oxaliplatin for stage II\/III rectal cancer: a 3-year follow-up study. Chin J Cancer Res. 2015;27:588\u201396.","journal-title":"Chin J Cancer Res"},{"key":"894_CR22","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1200\/JCO.2013.53.7753","volume":"32","author":"MJ O'Connell","year":"2014","unstructured":"O'Connell MJ, Colangelo LH, Beart RW, Petrelli NJ, Allegra CJ, Sharif S, et al. Capecitabine and oxaliplatin in the preoperative multimodality treatment of rectal cancer: surgical end points from National Surgical Adjuvant Breast and Bowel Project trial R-04. J Clin Oncol. 2014;32:1927\u201334.","journal-title":"J Clin Oncol"},{"key":"894_CR23","doi-asserted-by":"publisher","unstructured":"Allegra CJ, Yothers G, O'Connell MJ, Beart RW, Wozniak TF, Pitot HC, et al. Neoadjuvant 5-FU or Capecitabine plus radiation with or without oxaliplatin in rectal cancer patients: a phase iii randomized clinical trial. J Natl Cancer Inst. 2015;107(11):djv248. doi:\n10.1093\/jnci\/djv248\n\n. Print 2015 Nov. Erratum in: J Natl Cancer Inst. 2016;108(4):djw057. doi:\n10.1093\/jnci\/djw057\n\n. PMID:26374429.","DOI":"10.1093\/jnci\/djv248"},{"key":"894_CR24","doi-asserted-by":"publisher","unstructured":"An X, Lin X, Wang FH, Goodman K, Cai PQ, Kong LH, et al. Short term results of neoadjuvant chemoradiotherapy with fluoropyrimidine alone or in combination with oxaliplatin in locally advanced rectal cancer: a meta analysis. Eur J Cancer. 2013;49(4):843-51. doi:\n10.1016\/j.ejca.2012.09.026\n\n. Epub 2012 Oct 11.","DOI":"10.1016\/j.ejca.2012.09.026"},{"issue":"1","key":"894_CR25","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1186\/s12885-017-3323-4","volume":"17","author":"F De Felice","year":"2017","unstructured":"De Felice F, Benevento I, Magnante AL, Musio D, Bulzonetti N, Caiazzo R, Tombolini V. Clinical benefit of adding oxaliplatin to standard neoadjuvant chemoradiotherapy in locally advanced rectal cancer: a meta-analysis : Oxaliplatin in neoadjuvant treatment for rectal cancer. BMC Cancer. 2017;17(1):325.","journal-title":"BMC Cancer"},{"issue":"2","key":"894_CR26","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1200\/JCO.2007.12.7027","volume":"26","author":"ID Nagtegaal","year":"2008","unstructured":"Nagtegaal ID, Quirke P. What is the role for the circumferential margin in the modern treatment of rectal cancer? J Clin Oncol. 2008;26(2):303\u201312.","journal-title":"J Clin Oncol"},{"issue":"2","key":"894_CR27","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1097\/SLA.0b013e3181bdfc27","volume":"251","author":"E Fokas","year":"2010","unstructured":"Fokas E, Liersch T, Fietkau R, Smith KD, Tan D, Das P, et al. Clinical significance of acellular mucin in rectal adenocarcinoma patients with a pathologic complete response to preoperative chemoradiation. Ann Surg. 2010;251(2):261\u20134.","journal-title":"Ann Surg"},{"issue":"11","key":"894_CR28","doi-asserted-by":"crossref","first-page":"2863","DOI":"10.1245\/s10434-010-1119-8","volume":"17","author":"EJ Silberfein","year":"2010","unstructured":"Silberfein EJ, Kattepogu KM, Hu CY, Skibber JM, Rodriguez-Bigas MA, Feig B, et al. Long-term survival and recurrence outcomes following surgery for distal rectal cancer. Ann Surg Oncol. 2010;17(11):2863\u20139.","journal-title":"Ann Surg Oncol"},{"issue":"28","key":"894_CR29","doi-asserted-by":"crossref","first-page":"3753","DOI":"10.1200\/JCO.2011.34.9068","volume":"29","author":"UB Patel","year":"2011","unstructured":"Patel UB, Taylor F, Blomqvist L, George C, Evans H, Tekkis P, et al. Magnetic resonance imaging-detected tumor response for locally advanced rectal cancer predicts survival outcomes: MERCURY experience. J Clin Oncol. 2011;29(28):3753\u201360.","journal-title":"J Clin Oncol"},{"issue":"1","key":"894_CR30","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.radonc.2013.10.026","volume":"110","author":"B Engels","year":"2014","unstructured":"Engels B, Platteaux N, Van den Begin R, Gevaert T, Sermeus A, Storme G, et al. Preoperative intensity-modulated and image-guided radiotherapy with a simultaneous integrated boost in locally advanced rectal cancer: report on late toxicity and outcome. Radiother Oncol. 2014;110(1):155\u20139.","journal-title":"Radiother Oncol"},{"key":"894_CR31","doi-asserted-by":"crossref","first-page":"1114","DOI":"10.1056\/NEJMoa060829","volume":"355","author":"JF Bosset","year":"2006","unstructured":"Bosset JF, Collette L, Calais G, et al. Chemotherapy with preoperative radiotherapy in rectal cancer. N Engl J Med. 2006;355:1114\u201323.","journal-title":"N Engl J Med"},{"key":"894_CR32","doi-asserted-by":"crossref","first-page":"2773","DOI":"10.1200\/JCO.2010.34.4911","volume":"29","author":"C Aschele","year":"2011","unstructured":"Aschele C, Cionini L, Lonardi S, et al. Primary tumor response to preoperative chemoradiation with or without oxaliplatin in locally advanced rectal cancer: pathologic results of the STAR-01 randomized phase III trial. J Clin Oncol. 2011;29:2773\u201380.","journal-title":"J Clin Oncol"},{"issue":"2","key":"894_CR33","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.clon.2015.10.011","volume":"28","author":"R Glynne-Jones","year":"2016","unstructured":"Glynne-Jones R, Hughes R. Complete response after chemoradiotherapy in rectal cancer (watch-and-wait): have we cracked the code? Clin Oncol (R Coll Radiol). 2016;28(2):152\u201360.","journal-title":"Clin Oncol (R Coll Radiol)"},{"issue":"2","key":"894_CR34","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.radonc.2015.08.002","volume":"116","author":"S Matsusaka","year":"2015","unstructured":"Matsusaka S, Ishihara S, Kondo K, Horie H, Uehara K, Oguchi M, et al. A multicenter phase II study of preoperative chemoradiotherapy with S-1 plus oxaliplatin for locally advanced rectal cancer (SHOGUN trial). Radiother Oncol. 2015;116(2):209\u201313.","journal-title":"Radiother Oncol"},{"key":"894_CR35","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1016\/j.ijrobp.2008.10.017","volume":"74","author":"B Engels","year":"2009","unstructured":"Engels B, De Ridder M, Tournel K, et al. Preoperative helical tomotherapy and megavoltage computed tomography for rectal cancer: impact on the irradiated volume of small bowel. Int J Radiat Oncol Biol Phys. 2009;74:1476\u201380.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"894_CR36","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1016\/j.ijrobp.2008.02.032","volume":"71","author":"K Tournel","year":"2008","unstructured":"Tournel K, De Ridder M, Engels B, et al. Assessment of intrafractional movement and internal motion in radiotherapy of rectal cancer using megavoltage computed tomography. Int J Radiat Oncol Biol Phys. 2008;71:934\u20139.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"894_CR37","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.ijrobp.2011.05.068","volume":"83","author":"B Engels","year":"2012","unstructured":"Engels B, Tournel K, Everaert H, et al. Phase II study of preoperative helical tomotherapy with a simultaneous integrated boost for rectal cancer. Int J Radiat Oncol Biol Phys. 2012;83:142\u20138.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"894_CR38","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.1200\/JCO.2011.40.1836","volume":"30","author":"R Sauer","year":"2012","unstructured":"Sauer R, Liersch T, Merkel S, et al. Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: results of the German CAO\/ARO\/AIO-94 randomized phase III trial after a median follow-up of 11 years. J Clin Oncol. 2012;30:1926\u201333.","journal-title":"J Clin Oncol"},{"key":"894_CR39","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1002\/bjs.5506","volume":"10","author":"K Bujko","year":"2006","unstructured":"Bujko K, Nowacki MP, Nasierowska-Guttmejer A, et al. Long-term results of a randomized trial comparing preoperative short-course radiotherapy with preoperative conventionally fractionated chemoradiation for rectal cancer. Br J Surg. 2006;10:1215\u201323.","journal-title":"Br J Surg"},{"key":"894_CR40","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/S0360-3016(03)00073-7","volume":"56","author":"EJ Hall","year":"2003","unstructured":"Hall EJ, Wu C-S. Radiation-induced second cancers: the impact of 3D-CRT and IMRT. Int J Radiat Oncol Biol Phys. 2003;56:83\u20138.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"894_CR41","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/S1470-2045(11)70061-4","volume":"12","author":"A Berrington de Gonzalez","year":"2011","unstructured":"Berrington de Gonzalez A, Curtis RE, Kry SF, et al. Proportion of second cancers attributable to radiotherapy treatment in adults: a cohort study in the US SEER cancer registries. Lancet Oncol. 2011;12:353\u201360.","journal-title":"Lancet Oncol"},{"key":"894_CR42","doi-asserted-by":"crossref","first-page":"6126","DOI":"10.1200\/JCO.2005.02.543","volume":"23","author":"H Birgisson","year":"2005","unstructured":"Birgisson H, Pahlman L, Gunnarsson U, Glimelius B. Occurrence of second cancers in patients treated with radiotherapy for rectal cancer. J Clin Oncol. 2005;23:6126\u201331.","journal-title":"J Clin Oncol"},{"key":"894_CR43","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/S1470-2045(11)70097-3","volume":"12","author":"W van Gijn","year":"2011","unstructured":"van Gijn W, Marijnen CA, Nagtegaal ID, et al. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer: 12-years follow-up of the multicentre, randomised controlled TME trial. Lancet Oncol. 2011;12:575\u201382.","journal-title":"Lancet Oncol"}],"container-title":["Radiation Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13014-017-0894-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,9,21]],"date-time":"2017-09-21T05:45:41Z","timestamp":1505972741000},"score":1,"resource":{"primary":{"URL":"http:\/\/ro-journal.biomedcentral.com\/articles\/10.1186\/s13014-017-0894-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,9,21]]},"references-count":43,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["894"],"URL":"https:\/\/doi.org\/10.1186\/s13014-017-0894-9","relation":{},"ISSN":["1748-717X"],"issn-type":[{"value":"1748-717X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,9,21]]},"article-number":"156"}}